MabVax Therapeutics, Inc.
🇺🇸United States
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (100.0%)Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free
Phase 2
Completed
- Conditions
- Sarcoma
- First Posted Date
- 2010-06-10
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- MabVax Therapeutics, Inc.
- Target Recruit Count
- 136
- Registration Number
- NCT01141491
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸University of Colorado (Denver), Denver, Colorado, United States
🇺🇸Winship Cancer Institute at Emory Midtown, Atlanta, Georgia, United States
News
No news found